Abstract:
BACKGROUND:Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dose (MTD) of irinotecan chemotherapy according to the UGT1A1 genotype in previously treated lung cancer patients with the UGT1A1 *28 or UGT1A1 *6 polymorphism. METHODS:The eligibility criteria were as follows: lung cancer patients that had previously been treated with anticancer agents other than irinotecan, possessed the UGT1A1 *28 or UGT1A1 *6 polymorphism (group A included *28/*28, *6/*6, and *28/*6, and group B included *28 /- and *6 /-), were aged ≤75 years old, had a performance score of 0-1, and exhibited adequate bone marrow function. The patients were scheduled to receive irinotecan on days 1, 8, 15, 22, 29, and 36. RESULTS:Four patients were enrolled in this trial. Two patients were determined to be ineligible. The remaining two patients, who belonged to group B, received an initial irinotecan dose of 60 mg/m2 , but did not complete the planned treatment because of diarrhea and leukopenia. Thus, in group B patients, 60 mg/m2 was considered to be the MTD of irinotecan. The study was terminated in group A because of poor case recruitment. CONCLUSIONS:The MTD of irinotecan for previously treated lung cancer patients that are heterozygous for the UGT1A1 * 28 or UGT1A1 * 6 gene polymorphism is 60 mg/m2 .
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Fukuda M,Shimada M,Kitazaki T,Nagashima S,Hashiguchi K,Ebi N,Takayama K,Nakanishi Y,Semba H,Harada T,Seto T,Okamoto I,Ichinose Y,Sugio Kdoi
10.1111/1759-7714.12407subject
Has Abstractpub_date
2017-01-01 00:00:00pages
40-45issue
1eissn
1759-7706issn
1759-7714journal_volume
8pub_type
杂志文章相关文献
Thoracic Cancer文献大全abstract:BACKGROUND: The 12th National Lung Cancer Academic Conference was held in Wu Han, China in 2011. METHODS: The content of the conference involved recent research achievements and progress in the field of lung cancer, including the epidemiology of lung cancer and molecules, new methods and technology for early-screeni...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2012.00125.x
更新日期:2012-08-01 00:00:00
abstract:BACKGROUND:Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the effective medicines in advanced lung adenocarcinoma leptomeningeal metastasis (LM) treatment in recent years. METHODS:This paper reports two cases of advanced lung adenocarcinoma with exon-EGFR19 mutation. LM occurred during gefit...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12049
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13256
更新日期:2020-02-01 00:00:00
abstract::Here, we present a case of invasive thymoma with intraluminal growth into the left and right brachiocephalic veins, superior vena cava and the right atrium. Resection of the mass, double partial upper lobe lobectomy and superior vena cava, and left and right brachiocephalic vein replacement were performed. Pathologica...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13242
更新日期:2020-05-01 00:00:00
abstract:BACKGROUND:The efficacy of amrubicin for relapsed small-cell lung cancer (SCLC) has been reported in previous studies. Few reports, however, describe the efficacy and survival benefit of third-line amrubicin chemotherapy in patients with extensive disease (ED)-SCLC. METHODS:We retrospectively analyzed the clinical rec...
journal_title:Thoracic cancer
pub_type: 临床试验,杂志文章
doi:10.1111/1759-7714.13150
更新日期:2019-09-01 00:00:00
abstract:BACKGROUND:Rab27A and Rab27B are the major components of vesicle fusion and trafficking in exosome secretion and play important roles in tumor progression and metastasis. In addition, Rab27A and Rab27B are associated with tumor prognosis. This study investigated the prognostic roles of Rab27A and Rab27B expression in p...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12919
更新日期:2019-02-01 00:00:00
abstract::The main recurrence pattern for lung cancer patients after radical surgery is distant metastasis. The probability of pancreatic metastasis in patients diagnosed with lung squamous cell carcinoma is 0.02%, with a poor prognosis. Chemotherapy is the preferred treatment for recurrence. Single lesions or oligometastasis c...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13427
更新日期:2020-07-01 00:00:00
abstract:BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better progno...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12791
更新日期:2018-09-01 00:00:00
abstract:BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12847
更新日期:2018-11-01 00:00:00
abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13372
更新日期:2020-04-01 00:00:00
abstract::The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ...
journal_title:Thoracic cancer
pub_type: 杂志文章,评审
doi:10.1111/1759-7714.12613
更新日期:2018-04-01 00:00:00
abstract::Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanes...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12646
更新日期:2018-06-01 00:00:00
abstract:BACKGROUND:The abundance of tumor infiltrating CD8 T cells is an important parameter for antitumor effect of PD-1/PD-L1 immune checkpoint inhibitors, which is less in epidermal growth factor receptor (EGFR) mutation than wild-type non-small cell lung cancer (NSCLC). The mechanism still requires further study. METHODS:...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13504
更新日期:2020-08-01 00:00:00
abstract::Pleomorphic adenoma is the most common type of salivary gland tumor. Although it rarely affects the trachea and bronchus, it usually grows in the airway and presents as an endobronchial mass. We recently experienced a case of pleomorphic adenoma originating in the bronchus and growing outward into the mediastinum. We ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12013
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape. However, its role in non-small cell lung cancer (NSCLC) has not been reported. METHODS:Quantitative real-time PCR and Western blotting were used to evaluate TNFR2 in thr...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12948
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12232
更新日期:2015-09-01 00:00:00
abstract:BACKGROUND:The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS:All cases of lung cancer included in our prospective database between January 2000 and J...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12790
更新日期:2018-08-01 00:00:00
abstract:INTRODUCTION:VATS pulmonary segmentectomy is increasingly proposed as a parenchyma-sparing resection for tumors smaller than 2 cm in diameter. The aim of this study was to compare short-term oncological results and local control in solid non-small cell lung cancers (NSCLCs) <2 cm surgically treated by intentional VATS ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13766
更新日期:2020-12-03 00:00:00
abstract:BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13728
更新日期:2021-01-06 00:00:00
abstract:BACKGROUND:Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outc...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12150
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Approximately 8.3-15.9% of patients with clinical stage I non-small cell lung cancer are subsequently shown to have lymph node metastasis. However, the clinical characteristics of patients with lymph node metastasis in China are not fully understood. METHODS:This is a multicenter retrospective analysis of p...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12970
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND:This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS:Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chine...
journal_title:Thoracic cancer
pub_type: 杂志文章,meta分析
doi:10.1111/1759-7714.12783
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:The impact of adjuvant treatment for esophageal carcinoma with tumor-negative lymph nodes after upfront radical esophagectomy is still uncertain. This study investigated the effects of postoperative radiotherapy in pT1-3N0 esophageal carcinoma after radical resection. METHOD:We retrospectively identified pT...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13235
更新日期:2020-02-01 00:00:00
abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates from the pleura and has a poor prognosis. Eligible patients can benefit from surgery, but their survival is affected by many factors. Therefore, we created a graphic model that could predict the prognosis of surgically treate...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13063
更新日期:2019-05-01 00:00:00
abstract:BACKGROUND:The mortality rate from disseminated intravascular coagulation (DIC) is higher in patients with lung cancer than in non-lung cancer patients. Moreover, the prevalence of DIC varies among the pathologic types of lung cancer. This study analyzed the relationship between coagulation factors and the pathologic t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12766
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:Esophageal cancer has a high mortality rate, particularly in Asia, and there are obvious racial differences in regard to incidence. The purpose of our study was to assess the genetic susceptibility of functional single nucleotide polymorphisms in flap endonuclease-1 (FEN1) in esophageal squamous cell carcino...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12422
更新日期:2017-05-01 00:00:00
abstract::Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13785
更新日期:2021-01-12 00:00:00
abstract:BACKGROUND:Esophageal cancer is among the leading cancer types in Inner Mongolia. This study aimed to investigate the incidence and mortality rates of esophageal cancer in 2015 and the trends in these rates in the 2010-2015 period in this region. METHODS:National Colorectal Cancer Roundtable (NCCR) screening methods a...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13552
更新日期:2020-09-01 00:00:00
abstract::For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/j.1759-7714.2011.00086.x
更新日期:2012-02-01 00:00:00
abstract:BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13360
更新日期:2020-04-01 00:00:00